Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Colorectal Neoplasms 28Leukemia, Myeloid, Acute 27Neoplasms 26Recurrence 22Neoplasm Metastasis 22Multiple Myeloma 20Advanced Solid Tumors 20Lymphoma, B-Cell 19Breast Neoplasms 17Pancreatic Neoplasms 14Lung Neoplasms 13Glioblastoma 13Carcinoma, Hepatocellular 13Brain Neoplasms 13Lymphoma 12Glioma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Melanoma 11Hematologic Neoplasms 11Triple Negative Breast Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Ovarian Neoplasms 10Leukemia 10Advanced Solid Tumor 10Prostatic Neoplasms 9Head and Neck Neoplasms 9Lymphoma, Non-Hodgkin 8Esophageal Neoplasms 8Sarcoma 7

Interventions

irinotecan sucrosofate 1Oxaliplatin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × Advanced Small Intestine Cancer × Clear all
NCT07060014 2025-07-11

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

The Methodist Hospital Research Institute

Phase 1 Not yet recruiting
22 enrolled
Gastrointestinal

Advanced Small Intestine Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡